Evaluation of genetic toxicity of 6-diazo-5-oxo-l-norleucine (DON)

References

• Ames BN, McCann J, Yamasaki E. 1975. Methods for detecting carcinogens and mutagens with the Salmonella/mammalian microsome mutagenicity test. Mutat Res. 31:347–364.
   PubMed Web of Science ®Google Scholar
• Barclay RK, Garfinkel E, Philips M. 1956. Effects of DON on incorporation of precursors into nucleic acids. Proc Am Assoc Cancer Res. 2:93.
   Google Scholar
• Crosby H, Ihnat M, Miller K. 2015. Evaluating the toxicity of the analgesic glutaminase inhibitor 6-diazo-5-oxo-L-norleucine in vitro and on rat dermal skin fibroblasts. MOJ Toxicol. 1:00005.
   Google Scholar
• Crosby HA, Miller KE. 2016. Evaluating the analgesic effect of the GLS inhibitor 6-diazo-5-oxo-L-norleucine in vivo. Pharm Pharmacol Int J. 3:00055.
   Google Scholar
• Dion HW, Fusari SA, Jakubowski ZL, Zora JG, Bartz QR. 1956. 6-Diazo-5-oxo-L-norleucine, a new tumor-inhibitory substance. II. Isolation and characterization. J Am Chem Soc. 78:3075–3077.
   Web of Science ®Google Scholar
• Eidinoff ML, Knoll JE, Marano B, Cheong L. 1958. Effect of DON (6-diazo-5-oxo-L-norleucine) on incorporation of precursors into nucleic acid pyrimidines. Cancer Res. 18:105–109.
   Web of Science ®Google Scholar
• Fellows M, O’Donovan MR. 2007. Cytotoxicity in cultured mammalian cells is a function of the method used to estimate it. Mutagenesis. 22:275–280.
   PubMed Web of Science ®Google Scholar
• Galloway SM, Aardema MJ, Ishidate M Jr, Ivett JL, Kirkland DJ, Morita T, Mosesso P, Sofuni T. 1994. Report from working group on in vitro tests for chromosomal aberrations. Mutat Res. 312:241–261.
   PubMed Web of Science ®Google Scholar
• Ghosh S, Blumenthal HJ, Davidson E, Roseman S. 1960. Glucosamine metabolism. V. Enzymatic synthesis of glucosamine 6-phosphate. J Biol Chem. 235:1265–1273.
   PubMed Web of Science ®Google Scholar
• Green MHL, Muriel WJ. 1976. Mutagen testing using trp + reversion in Escherichia coli. Mutat Res. 38:3–32.
   PubMed Web of Science ®Google Scholar
• Hiramoto K, Fujino T, Kikugawa K. 1996. DNA strand cleavage by tumor-inhibiting antibiotic 6-diazo-5-oxo-L-norleucine. Mutat Res. 360:95–100.
   PubMed Web of Science ®Google Scholar
• Hoffman EM, Miller KE. 2010. Peripheral inhibition of glutaminase reduces carrageenan-induced Fos expression in the superficial dorsal horn of the rat. Neurosci Lett. 472:157–160.
   PubMed Web of Science ®Google Scholar
• International Conference on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Adopted at Step 5 in US by FDA on June 7, 2012. S2(R1) document recommended for adoption at step 4 of the ICH process on 9 November 2011. Adopted at Step 5 in Europe by CHMP December 2011 (issued as EMA/CHMP/ICH/126642/2008). (issued as 77 FR 33748 pages 33748-33749). Japan Step 5 adoption in process.
   Google Scholar
• Kastenbaum MA, Bowman KO. 1970. Tables for determining the statistical significance of mutation frequencies. Mutation Res. 9:527–549.
   PubMed Web of Science ®Google Scholar
• Katoh Y, Maekawa M, Sano Y. 1995. Mutagenicity of o-diazoacetyl-L-serine (azaserine) and 6-diazo-5-ozo-L-norleucine (DON) in a soybean test system. Mutation Res. 342:37–41.
   PubMed Web of Science ®Google Scholar
• Lilja HS, Longneckar DS, Yager JD Jr. 1981. Studies of DNA damage in rat pancreas and liver by 6-diazo-5-oxo-L-norleucine, ethyl diazoacetate and azaserine. Cancer Lett. 12:139–146.
   PubMed Web of Science ®Google Scholar
• Lorge E, Hayashi M, Albertini S, Kirkland D. 2008. Comparison of different methods for an accurate assessment of cytotoxicity in the in vitro micronucleus test. Mutation Res. 655:4–21.
   PubMed Web of Science ®Google Scholar
• Miller KE. 2010. Method of alleviating chronic pain via peripheral glutaminase regulation. US Patent 7,714,007 B2.
   Google Scholar
• Miller KE, Hoffman EM, Sutharshan M, Schechter R. 2011. Glutamate pharmacology and metabolism in peripheral primary afferents: physiological and pathophysiological mechanisms. Pharmacol Ther. 130:283–309.
   PubMed Web of Science ®Google Scholar
• Moore EC, LePage GA. 1957. In vivo sensitivity of normal and neoplastic mouse tissues to azaserine. Cancer Res. 17:804–808.
   PubMed Web of Science ®Google Scholar
• Mueller C, Al-Batran S, Jaeger E, Schmidt B, Bausch M, Unger C, Sethuraman N. 2008. A phase IIa study of PEGylated glutaminase (PEG-PGA) plus 6-diazo-5-oxo-L-norleucine (DON) in patients with advanced refractory solid tumors [abstract]. J Clin Oncol. 26:2533.
   Web of Science ®Google Scholar
• Nishio M, Tsurodome M, Bando H, Komada H, Ito Y. 1990. Antiviral effect of 6-diazo-5-oxo-L-norleucine, antagonist of gama-glutamyl transpeptidase, on replicationof human parainfluenza virus type 2. J Gen Virol. 71:61–67.
   PubMed Web of Science ®Google Scholar
• Preston RJ, Au W, Bender MA, Brewen JG, Carrano AV, Heddle JA, McFee AF, Wolff S, Wassom JS. 1981. Mammalian in vivo and in vitro cytogenetic assays: a report of the Gene Tox Program. Mutation Res. 87:143–188.
   PubMed Web of Science ®Google Scholar
• Prival MJ, Mitchell VD. 1982. Analysis of a method for testing azo dyes for mutagenic activity in Salmonella typhimurium in the presence of flavin mononucleotide and hamster liver S9. Mutat Res. 97:103–116.
   PubMed Web of Science ®Google Scholar
• Schmid W. 1975. The micronucleus test. Mutation Res. 31:9–15.
   PubMed Web of Science ®Google Scholar
• Scott D, Danford ND, Dean BJ, Kirkland DJ. 1990. Metaphase chromosome aberration assays in vitro. In: Basic mutagenicity tests: UKEMS recommended procedures. In: Kirkland DJ, editor. New York (NY): Cambridge University Press.
   Google Scholar
• Staiano N, Everson RB, Cooney DA, Longnecker DS, Thorgeirsson SS. 1980. Mutagenicity of D-and L-azaserine, 6-diazo-5-oxo-L-norleucine and N-(N-methyl-N-nitroso-carbamyl)-L-ornithine in the salmonella test system. Mutat Res. 79:387–390.
   PubMed Web of Science ®Google Scholar
• Swierenga SHH, Heddle JA, Sigal EA, Gilman JPW, Brillinger RL, Douglas GR, Nestmann ER. 1991. Recommended protocols based on a survey of current practice in genotoxicity testing laboratories, IV. Chromosome aberration and sister-chromatid exchange in Chinese hamster ovary, V79 Chinese lung and human lymphocyte cultures. Mutat Res. 246:301–322.
   PubMed Web of Science ®Google Scholar
• The Organization for Economic Co-operation and Development (OECD). 1997. OECD Guidelines for Testing of Chemicals. Guideline 471 (Bacterial Reverse Mutation Test). Adopted 21st July 1997.
   Google Scholar
• The Organization for Economic Co-operation and Development (OECD). 1997. OECD Guidelines for Testing of Chemicals. Guideline 474 (Genetic Toxicology: Mammalian Erythrocyte Micronucleus Test). Updated guidance adopted 21st July. Paris (UK): OECD.
   Google Scholar
• The Organization for Economic Co-operation and Development (OECD). 1998. OECD Guideline for the Testing of Chemicals, Guideline 473 (In Vitro Mammalian Chromosome Aberration Test). February 1998. Ninth Addendum to the OECD Guidelines for the Testing of Chemicals. Paris (UK): OECD.
   Google Scholar
• Wu F, Lukinius A, Bergstrom M, Eriksson B, Watanabe Y, Langstrom B. 1999. A mechanism behind the antitumour effect of 6-diazo-5-oxo-L-norleucine (DON): disruption of mitochondria. Eur J Cancer (Oxford, England: 1990). 35:1155–1161.
   PubMed Web of Science ®Google Scholar
• Yahagi T, Nagao M, Seino Y, Matsushima T, Sugimura T. 1977. Mutagenicities of N-nitrosamines on Salmonella. Mutat Res. 48:121–130.
   PubMed Web of Science ®Google Scholar